Executive Summary
The USA Corporate Distress & Bankruptcy stream for August 28, 2026, reveals a severe wave of Nasdaq and NYSE American non-compliance events, with 14 filings concentrated on going concern warnings, delisting notices, and bankruptcy proceedings.
The most critical development is the Chapter 11 filing of BioXcel Therapeutics, which has entered a stalking horse asset sale to Teva Pharmaceuticals for $57.5 million upfront, signaling a distressed exit for a biotech firm. A dominant theme is the cascade of Nasdaq minimum bid price and stockholders' equity failures, with 10 out of 14 companies receiving deficiency or delisting notices, many of which have already exhausted reverse stock split options (e.g., KALA BIO, GeoVax Labs). Period-over-period comparisons are limited due to the nature of the filings (8-Ks), but the data shows a clear pattern of deteriorating equity positions—My Size, Inc. reported equity of $2.347 million (below the $2.5 million threshold), and Oragenics Inc. reported $3.7 million (below $4 million). Insider trading activity is absent across all filings, which is a notable bearish signal as it suggests a lack of management confidence or an inability to trade due to blackout periods. Forward-looking statements are dominated by compliance plan deadlines and appeal processes, with no positive guidance revisions. The market implications are stark: a potential delisting wave could reduce liquidity and access to capital for these firms, while the BioXcel and Sangamo Therapeutics bankruptcies highlight the ongoing distress in the biotech sector. Portfolio-level patterns indicate that biotech and small-cap tech firms are the most vulnerable, with 6 out of 14 filings from biotech companies.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US Corporate Distress Financial Stress SEC Filings digest from August 21, 2026.
Investment Signals (10)
- BioXcel Therapeutics ↓ (BEARISH)▲
Chapter 11 filing with a stalking horse bid from Teva Pharmaceuticals at $57.5M upfront plus up to $87.5M in milestones; this provides a floor valuation and a potential exit for shareholders, but the stock is likely to be worthless post-restructuring
- Sangamo Therapeutics ↓ (BEARISH)▲
Chapter 11 asset sale of Fabry disease gene therapy to PTC Therapeutics; the stalking horse bid and potential auction could yield some recovery for creditors, but equity holders face near-total loss
- KALA BIO ↓ (BEARISH)▲
Received a delisting notice after a 1-for-50 reverse split failed to maintain the $1 bid price; this signals extreme shareholder dilution and a high probability of OTC trading, making the stock highly speculative
- GeoVax Labs ↓ (BEARISH)▲
Dual non-compliance (bid price and stockholders' equity) after a 1-for-25 reverse split; the company faces a September 3 hearing deadline, and failure could lead to delisting, with no insider buying to signal confidence
- JUPITER NEUROSCIENCES ↓ (BEARISH)▲
Regained bid price compliance but faces delisting for market value deficiency; this mixed signal suggests the company is struggling to maintain listing standards, and the stock remains risky
- Netcapital Inc. ↓ (BEARISH)▲
Nasdaq delinquency notice for late 10-K filing; the company has 60 days to submit a compliance plan, but the lack of insider activity and negative sentiment indicate a high risk of continued non-compliance
-
Stockholders' equity of $2.347M vs. $2.5M requirement; the company has 45 days to submit a plan, but the equity shortfall is small, suggesting a potential quick fix (e.g., capital raise) if management acts [NEUTRAL/BEARISH]
- Socket Mobile, Inc. ↓ (BEARISH)▲
Equity of $2.382M below $2.5M threshold, and also fails alternative standards (market value and net income); this triple deficiency makes compliance challenging, and the stock is at high risk of delisting
- Envirotech Vehicles (Azio AI Holdings) (NEUTRAL)▲
Remediated a change-of-control violation by removing four executives; this swift action shows management responsiveness, but the underlying business transformation remains unproven
- Shuttle Pharmaceuticals Holdings ↓ (BEARISH)▲
Late 10-Q filing with a 60-day compliance plan deadline; the company has no insider buying and negative sentiment, indicating a lack of confidence in timely filing
Risk Flags (10)
- BioXcel Therapeutics/Chapter 11 Bankruptcy↓ [HIGH RISK]▼
The company is in full bankruptcy proceedings with a stalking horse sale; equity holders are likely to be wiped out, and the stock is essentially worthless
- Sangamo Therapeutics/Chapter 11 Bankruptcy↓ [HIGH RISK]▼
Similar to BioXcel, the asset sale under Section 363 means equity holders will likely receive no recovery; the stock is a high-risk speculative play
- KALA BIO/Delisting Risk↓ [HIGH RISK]▼
The company has already used a reverse split and now faces delisting; trading on OTC will severely reduce liquidity and price, making it a near-zero recovery scenario
- GeoVax Labs/Dual Non-Compliance↓ [HIGH RISK]▼
The company faces both bid price and equity deficiencies; the hearing deadline is September 3, 2026, and failure to appeal will lead to immediate suspension on September 8
- JUPITER NEUROSCIENCES/Market Value Deficiency↓ [MEDIUM RISK]▼
Despite regaining bid price compliance, the market value deficiency persists; the company is in a precarious position with no guarantee of maintaining listing
- My Size, Inc./Equity Deficiency↓ [MEDIUM RISK]▼
The equity shortfall is small ($153K), but the company has no clear path to compliance; if a capital raise fails, delisting is imminent
- Socket Mobile, Inc./Triple Deficiency↓ [HIGH RISK]▼
The company fails all three listing standards (equity, market value, net income); this is a severe distress signal, and delisting is highly likely
- Oragenics Inc./Equity Shortfall↓ [HIGH RISK]▼
Stockholders' equity of $3.7M is below the $4M threshold; the company has until September 25, 2026, to submit a plan, but net losses for five years indicate a structural problem
- GULF RESOURCES, Inc./Delinquent Filings↓ [MEDIUM RISK]▼
The company has failed to file both Q1 and Q2 2026 10-Qs, despite being granted an extension; this pattern of late filings suggests deeper accounting or operational issues
- AIRWA Inc./Delayed 10-K↓ [MEDIUM RISK]▼
The company failed to file its annual report due to acquisition-related consolidation delays; this is a red flag for integration issues and potential goodwill impairment
Opportunities (8)
-
The Teva bid provides a valuation floor; if a higher bid emerges in the auction, creditors may recover more, but equity holders should avoid this as a recovery play [OPPORTUNITY for distressed debt investors]
-
The stalking horse bid from PTC could attract a higher bid; investors with deep knowledge of the Fabry disease asset might find value in the bankruptcy process [OPPORTUNITY for distressed debt investors]
- Envirotech Vehicles (Azio AI Holdings)/Remediation Success (SPECULATIVE OPPORTUNITY)◆
The company quickly resolved a Nasdaq violation by removing executives; this shows management is proactive, and the stock could rebound if the AI transformation gains traction
- My Size, Inc./Small Equity Gap↓ (SPECULATIVE OPPORTUNITY)◆
The $153K equity shortfall is small; if the company can raise capital or improve equity quickly, the stock could avoid delisting and trade higher
- JUPITER NEUROSCIENCES/Bid Price Compliance↓ (SHORT-TERM OPPORTUNITY)◆
The company regained bid price compliance, which could attract short-term momentum traders; however, the market value deficiency remains a risk
- Netcapital Inc./60-Day Window↓ (SPECULATIVE OPPORTUNITY)◆
The company has until October 23 to submit a compliance plan; if they file the 10-K quickly, the stock could see a relief rally
- Shuttle Pharmaceuticals Holdings/60-Day Window↓ (SPECULATIVE OPPORTUNITY)◆
Similar to Netcapital, a timely 10-Q filing could resolve the delinquency and boost investor confidence
- Oragenics Inc./Extended Compliance Period↓ (SPECULATIVE OPPORTUNITY)◆
The company has until February 25, 2028, to regain compliance; this long runway provides time for a turnaround, but the stock remains highly speculative
Sector Themes (5)
- Biotech Distress Wave◆
6 out of 14 filings are from biotech companies (BioXcel, KALA BIO, JUPITER NEUROSCIENCES, GeoVax, Oragenics, Sangamo), indicating a sector-wide struggle with cash burn, failed clinical trials, and delisting risks. This suggests a bearish outlook for small-cap biotech, with potential for consolidation via distressed M&A.
- Reverse Split Ineffectiveness◆
Three companies (KALA BIO, GeoVax Labs, and JUPITER NEUROSCIENCES) had already executed reverse stock splits but still failed to maintain compliance. This pattern shows that reverse splits are often a temporary fix and can signal terminal decline, as they dilute shareholders and fail to address underlying business issues.
- Late Filing Epidemic◆
5 companies (Netcapital, Shuttle Pharmaceuticals, GULF RESOURCES, AIRWA, and BioAtla) are delinquent on SEC filings (10-K or 10-Q). This is a red flag for accounting controls, potential fraud, or operational distress, and it often precedes more severe consequences like bankruptcy.
- Stockholders' Equity Crisis◆
4 companies (My Size, Socket Mobile, Oragenics, and GeoVax) are non-compliant with minimum equity requirements. This indicates a systemic capital deficiency across small-cap firms, likely driven by sustained net losses and inability to raise funds in a tight market.
- Bankruptcy as a Strategic Exit◆
Both BioXcel and Sangamo have chosen Chapter 11 to sell assets via stalking horse bids, rather than attempting to reorganize. This trend suggests that for cash-strapped biotechs, bankruptcy is becoming a preferred method to maximize asset value, but it leaves equity holders with nothing.
Watch List (8)
-
Bankruptcy auction process; watch for higher bids than Teva's $57.5M stalking horse, with a deadline of October 30, 2026, for consummation. The outcome will determine recovery for creditors.
-
Bankruptcy auction for Fabry disease asset; stalking horse bid from PTC Therapeutics, with court approval expected soon. Watch for competing bids that could increase recovery.
-
Nasdaq hearing request; the company must appeal the delisting determination. If the hearing is denied, the stock will trade OTC, leading to a sharp price decline.
-
Hearing deadline on September 3, 2026; if the company fails to request a hearing, trading will be suspended on September 8. Watch for any last-minute compliance efforts.
-
Compliance plan due by October 9, 2026; the company must address the $2.5M equity shortfall. A capital raise or equity injection could resolve the issue, but failure leads to delisting.
-
Compliance plan due by October 8, 2026; the triple deficiency makes this a high-risk watch. Any news of a strategic transaction or capital infusion would be critical.
-
Compliance plan due by September 25, 2026; the company has until February 25, 2028, to regain compliance. Watch for any operational turnaround or financing announcements.
-
Final delisting effective August 31, 2026; the stock will move to OTC. Watch for any strategic alternatives announcement, as the company is exploring options to maximize shareholder value.
Filing Analyses
(14)
28-08-2026
Netcapital Inc. received a Nasdaq delinquency notice on August 24, 2026, for failing to file its Annual Report (Form 10-K) for the fiscal year ended April 30, 2026, violating Listing Rule 5250(c)(1). The company has 60 days (until October 23, 2026) to submit a compliance plan, with a possible extension to February 9, 2027. While the notice has no immediate effect on trading, non-compliance will be publicly broadcast, and there is no assurance Nasdaq will accept the plan or that compliance can be regained.
- · The delinquency notification was received on August 24, 2026, and the 8-K was filed on August 28, 2026.
- · The company's common stock (NCPL) and warrants (NCPLW) are listed on Nasdaq.
- · If the compliance plan is not accepted, the company can appeal to a Nasdaq Hearings Panel under Rule 5815(a).
- · A press release announcing the notice was issued on August 28, 2026, and is attached as Exhibit 99.1.
28-08-2026
BioXcel Therapeutics has filed for Chapter 11 bankruptcy and entered into a stalking horse asset purchase agreement with Teva Pharmaceuticals. Teva will acquire substantially all of the company's assets for $57.5 million upfront cash plus assumption of liabilities, with additional contingent milestone payments of up to $67.5 million for the pending sNDA for IGALMI® at-home use and up to $20 million in commercial milestone payments. The company has appointed Samir Saleem as Chief Restructuring Officer to oversee the restructuring process, and the transaction is subject to court approval and higher bids.
- · The stalking horse bid serves as the minimum floor bid, and the transaction is subject to higher or otherwise better bids in an auction process.
- · The transaction must be consummated by October 30, 2026, or either party may terminate the agreement.
- · The company has appointed a Strategic Process Committee of the Board to evaluate and implement restructuring or sale transactions.
- · Teva has agreed to serve as the stalking horse bidder, and the company has filed a motion under Section 363 of the Bankruptcy Code to sell assets.
28-08-2026
KALA BIO, Inc. received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company that its common stock has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days (July 16, 2026 through August 26, 2026). Because the company had already effected a 1-for-50 reverse stock split on May 11, 2026, Nasdaq has determined that KALA is not eligible for the standard 180-day compliance period. The company intends to appeal the determination by requesting a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting pending the Panel's decision, though there is no assurance of a favorable outcome.
- · The company's common stock trades under the symbol KALA on The Nasdaq Capital Market.
- · The non-compliance period ran from July 16, 2026 through August 26, 2026.
- · The company had previously effected a 1-for-50 reverse stock split on May 11, 2026, which disqualified it from the standard 180-day compliance period.
- · A timely request for a hearing will stay any suspension or delisting action pending the Panel's decision.
28-08-2026
Jupiter Neurosciences received a delisting notice from Nasdaq on August 27, 2026, because its market value of listed securities remained below the $35 million minimum for over 30 consecutive trading days and it failed to regain compliance by the August 25, 2026 deadline. The company intends to appeal the determination and request a hearing before the Nasdaq Hearings Panel, which would stay further action pending a final decision. However, the company did regain compliance with the $1.00 minimum bid price requirement as of August 26, 2026, though it cannot assure it will maintain that compliance.
- · The delisting notice was received on August 27, 2026, and the compliance deadline was August 25, 2026.
- · The company had previously been notified on February 26, 2026, of the market value deficiency.
- · The company regained compliance with the minimum bid price rule ($1.00 per share) for the 10 consecutive business days ending August 26, 2026.
- · There is no assurance that the appeal will be successful or that the company will maintain bid price compliance.
28-08-2026
GeoVax Labs, Inc. received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company that its common stock will be delisted due to non-compliance with the minimum $1.00 bid price requirement. The closing bid price remained below $1.00 for 30 consecutive business days from July 16, 2026 through August 26, 2026, and the company is ineligible for a customary compliance period because it effected a 1-for-25 reverse stock split on January 12, 2026. GeoVax also faces a separate deficiency regarding the minimum $2,500,000 stockholders' equity requirement. The company plans to request a hearing before the Nasdaq Hearings Panel by September 3, 2026, which will stay any suspension; however, there is no assurance that continued listing will be granted.
- · Trading suspension expected at the opening of business on September 8, 2026 if no timely hearing request is made.
- · Deadline to request a hearing is September 3, 2026.
- · Company also faces non-compliance with the minimum $2,500,000 stockholders' equity requirement under Nasdaq Listing Rule 5550(b).
28-08-2026
Envirotech Vehicles, Inc. (now Azio AI Holdings) received a Nasdaq deficiency notice on August 28, 2026, for failing to obtain shareholder approval before completing a change-of-control merger on July 2, 2026, which triggered the appointment of five Azio AI-affiliated executives. However, the company remediated the issue by removing four of those executives (Simon Yu, David Shiue, Gary Chen, Jenny Yang) effective August 27, 2026, and Nasdaq has closed the matter. Chris Young remains CEO, and the delisting notice has no immediate effect on listing, though the company must still comply with other continued listing requirements.
- · The deficiency was under Nasdaq Listing Rule 5635(b) regarding shareholder approval for change-of-control issuances.
- · The merger closed on July 2, 2026, and the deficiency was remediated by August 27, 2026.
- · Simon Yu remains employed by the company but is no longer an executive officer or Section 16 officer.
- · The company's common stock trades under the symbol AZIO on the Nasdaq Capital Market.
28-08-2026
My Size, Inc. received a Nasdaq deficiency letter on August 25, 2026, for failing to meet the minimum stockholders' equity requirement of $2,500,000, reporting only $2,347,000 as of June 30, 2026. The company has 45 days (until October 9, 2026) to submit a compliance plan and may receive up to 180 additional days to regain compliance. There is no immediate impact on listing, but failure to regain compliance could lead to delisting.
- · The deficiency letter was received on August 25, 2026, and the 8-K was filed on August 28, 2026.
- · The company has until October 9, 2026, to submit a compliance plan.
- · If the compliance plan is accepted, Nasdaq may grant an extension through February 21, 2027.
- · If the compliance plan is not accepted or compliance is not regained, the Staff would issue a delisting determination, and the company could request a hearing to stay delisting.
28-08-2026
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) received a Nasdaq notice on August 28, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2026, violating Nasdaq Listing Rule 5250(c)(1). The company has 60 days (until October 27, 2026) to submit a compliance plan, and if accepted, Nasdaq may grant an exception until February 22, 2027. While the notice does not immediately affect trading, failure to regain compliance could lead to delisting, and there is no assurance the plan will be accepted.
- · The company's common stock trades under the symbol SHPH on Nasdaq.
- · If Nasdaq does not accept the compliance plan, the company may appeal to a hearings panel.
- · Nasdaq will broadcast a noncompliance indicator over its market data network.
- · The company is working diligently to complete and file the Form 10-Q as soon as practicable.
28-08-2026
Gulf Resources, Inc. (GURE) received a Nasdaq notice on August 24, 2026, for failing to timely file its Q2 2026 Form 10-Q, violating Listing Rule 5250(c)(1). The company had previously been granted an extension until August 31, 2026, to file its delinquent Q1 2026 Form 10-Q, but as of this report, both the Q1 and Q2 2026 Form 10-Qs remain unfiled. While the notice has no immediate effect on listing, the company must submit an updated compliance plan by August 28, 2026, and the ongoing delinquency poses a continued risk to its Nasdaq listing.
- · The company filed its delinquent 2025 Form 10-K on August 17, 2026, and is no longer delinquent on that filing.
- · Amendments to the 2024 Form 10-K were filed on July 27, 2026, and August 24, 2026.
- · The company remains delinquent in filing both the Q1 2026 Form 10-Q and the Q2 2026 Form 10-Q as of the press release date.
- · The company's common stock trades on the Nasdaq Capital Market under the symbol GURE.
28-08-2026
Oragenics Inc. received a notice from NYSE American on August 26, 2026, for non-compliance with continued listing standards due to stockholders' equity of $3.7M at June 30, 2026 (below the $4M/$6M thresholds) and net losses in its last five fiscal years. The company must submit a compliance plan by September 25, 2026, and has until February 25, 2028 to regain compliance; if unsuccessful, it faces potential delisting, which could reduce liquidity, market price, and access to capital.
- · Equity shortfall: $3.7M vs. $4M (Section 1003(a)(ii)) and $6M (Section 1003(a)(iii)).
- · Common stock will trade with '.BC' designation (below compliance) but remains listed during the review period.
- · Plan deadline: September 25, 2026; compliance deadline: February 25, 2028.
- · Net losses reported in last five fiscal years ended December 31, 2025.
28-08-2026
Socket Mobile, Inc. received a Nasdaq deficiency notice on August 24, 2026, for failing to meet the minimum stockholders' equity requirement of $2.5 million, reporting equity of only $2,382,624 as of June 30, 2026. The company also does not meet alternative listing standards based on market value of listed securities ($35 million minimum) or net income from continuing operations ($500,000 minimum). While the notice has no immediate effect on trading, Socket Mobile must submit a compliance plan by October 8, 2026, and faces potential delisting if it cannot regain compliance within a possible 180-day extension.
- · The company also failed alternative listing standards under Rule 5550(b)(2) (market value of listed securities at least $35 million) and Rule 5550(b)(3) (net income from continuing operations at least $500,000 in the most recent fiscal year or two of the last three).
- · If Nasdaq does not accept the compliance plan, the company may appeal to a Nasdaq Hearings Panel.
- · The notice has no immediate effect on trading; shares continue to trade on Nasdaq under symbol SCKT.
28-08-2026
AiRWA Inc. received a delisting notice from Nasdaq on August 24, 2026, for failing to file its Annual Report on Form 10-K for the period ended April 30, 2026, due to delays in consolidating financial results from a significant acquisition. The company has 60 days to submit a compliance plan and potentially up to 180 days from the filing due date to regain compliance, but there is no assurance of success. The company issued a press release on August 28, 2026, disclosing the notice.
- · The delisting notice was triggered by failure to file the Annual Report on Form 10-K for the period ended April 30, 2026.
- · The delay was attributed to the time-consuming consolidation of financial results from a significant acquisition.
- · If Nasdaq accepts the compliance plan, the company has until January 25, 2027, to regain compliance.
- · The company expects to file the Form 10-K before the October 23, 2026, deadline for plan submission.
- · There is no assurance that the company will be able to satisfy Nasdaq's continued listing requirements.
28-08-2026
BioAtla, Inc. (BCAB) received a final delisting determination from Nasdaq's Listing Council on August 26, 2026, affirming the earlier Panel decision to delist its common stock due to non-compliance with the $1.00 bid price requirement and failure to demonstrate compliance with the $2.5 million stockholders' equity requirement. Trading on Nasdaq is expected to be suspended at the opening of business on August 31, 2026, unless the Nasdaq Board calls the matter for review. The company expects its shares to be eligible for quotation on the OTC Markets system under the same symbol BCAB, but warns this may materially adversely affect trading price and volume. The company's ongoing strategic process to explore options to maximize shareholder value, initiated in March 2026, continues with no assurance of any resulting agreements or transactions.
- · The company had previously received a delisting determination on February 6, 2026, and had requested a review by the Listing Council, which stayed the suspension pending its review.
- · The Listing Council's decision to affirm the delisting was issued on August 26, 2026.
- · Unless the Nasdaq Board calls the matter for review, trading will be suspended at the opening of business on August 31, 2026, and a Form 25-NSE will be filed with the SEC.
- · The company expects its common stock to be immediately eligible for quotation on OTC Markets under the symbol BCAB, but there is no assurance a market will develop or be maintained.
- · The company's strategic process to explore options to maximize shareholder value, initiated in March 2026, is ongoing with no assurance of any resulting agreements or transactions.
28-08-2026
Sangamo Therapeutics, Inc. (SGMO) has entered into a definitive Asset Purchase Agreement to sell substantially all assets of its Fabry disease gene therapy business (ST-920) to PTC Therapeutics, Inc. for an undisclosed closing consideration plus potential milestone payments. The sale is being conducted under Chapter 11 bankruptcy (filed June 23, 2026, Case No. 26-10989 in Delaware), subject to Bankruptcy Court approval via a sale order under Sections 105, 363, and 365 of the Bankruptcy Code. The agreement includes an auction process with a stalking horse bid, and the transaction is expected to close following court approval.
- · Sangamo filed for Chapter 11 bankruptcy on June 23, 2026 (Petition Date).
- · The asset sale is subject to a Bankruptcy Court-approved auction and sale order.
- · PTC Therapeutics is the stalking horse buyer; a backup bidder may emerge from the auction.
- · The agreement includes an Accelerated Milestone Payment upon first accelerated FDA approval of a BLA for ST-920 based on the STAAR Studies.
- · The purchase price (Closing Consideration) is not disclosed in the filing excerpt.
- · The Business is defined as developing and investigating a gene therapy product for Fabry disease (ST-920).
- · The agreement includes a Transition Services Agreement to be executed at closing.
- · Seller retains a non-exclusive license to certain intellectual property assets post-closing.
Get daily alerts with 10 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 14 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Corporate Distress Financial Stress SEC Filings
August 20, 2026
US Corporate Distress Financial Stress SEC Filings — August 20, 2026
August 19, 2026
US Corporate Distress Financial Stress SEC Filings — August 19, 2026
August 18, 2026
US Corporate Distress Financial Stress SEC Filings — August 18, 2026
August 17, 2026
US Corporate Distress Financial Stress SEC Filings — August 17, 2026
🇺🇸 More from United States
View all →August 21, 2026
S&P 500 Consumer Discretionary Sector SEC Filings — August 21, 2026
S&P 500 Consumer Discretionary Sector SEC Filings
August 21, 2026
US Executive Compensation Proxy SEC Filings — August 21, 2026
US Executive Compensation Proxy SEC Filings
August 21, 2026
US Merger & Acquisition SEC Filings — August 21, 2026
US Merger & Acquisition SEC Filings
August 21, 2026
USA Insider Trading Pulse — August 21, 2026
USA Insider Trading Pulse